Azenta (AZTA)
(Real Time Quote from BATS)
$52.24 USD
-0.30 (-0.57%)
Updated Apr 24, 2024 01:12 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Azenta (AZTA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$69.60 | $79.00 | $60.00 | 32.47% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Azenta comes to $69.60. The forecasts range from a low of $60.00 to a high of $79.00. The average price target represents an increase of 32.47% from the last closing price of $52.54.
Analyst Price Targets (5 )
Broker Rating
Azenta currently has an average brokerage recommendation (ABR) of 2.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.50 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, one is Strong Buy and one is Buy. Strong Buy and Buy each account for 14.29% of all recommendations. A month ago, Strong Buy made up 16.67%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 5 | 5 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.57 | 2.57 | 2.50 | 2.50 | 2.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/4/2024 | Evercore Partners | Vijay Kumar | Hold | Hold |
3/21/2024 | KeyBanc Capital Markets | Paul Knight | Hold | Hold |
3/15/2024 | Raymond James | Andrew Cooper | Hold | Hold |
3/7/2024 | Needham & Company | David Saxon | Moderate Buy | Moderate Buy |
2/1/2024 | B. Riley Securities | Yuan Zhi | Strong Buy | Strong Buy |
11/14/2023 | Stephens | Jacob Johnson | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.57 |
ABR (Last week) | 2.57 |
# of Recs in ABR | 7 |
Average Target Price | $69.60 |
LT Growth Rate | NA |
Industry | Medical Info Systems |
Industry Rank by ABR | 91 of 252 |
Current Quarter EPS Est: | 0.07 |